Abstract
Aims and background. Small cell lung cancer is an aggressive histologic subtype of lung cancer in which the role of chemotherapy and radiotherapy has been well established in limited-stage disease. We retrospectively reviewed a series of limitedstage small cell lung cancers treated with chemotherapy and thoracic and brain radiotherapy. Methods and study design. A total of 124 patients affected by limited-stage small cell lung cancer has been treated over 10 years in our Institute. Fifty-three patients (42.8%) had concomitant radio-chemotherapy treatment and 71 patients (57.2%) a sequential treatment. Eighty-eight patients (70.9%) underwent an association of a platinum-derived drug (cisplatinum or carboplatinum) and etoposide. Prophylactic cranial irradiation was planned in all patients with histologically proven complete response to primary radio-chemotherapy. Results. With a mean follow-up of 2.2 years, complete response was obtained in 50.8% of cases. We found a significant difference between different radio-chemotherapy association approaches (P = 0.007): percentages of overall survival were respectively 10.0%, 12.9% and 5.6% in early, late concomitant and sequential radiochemotherapy timing. Cranial prophylaxis did not seem to influence overall survival (P = 0.21) or disease-free survival for local relapse (P = 0.34). Conclusions. Concomitant radio-chemotherapy is the best approach according to our experience. Our results show a benefit of prophylactic cranial irradiation in distant metastasis-free survival. Copyright - Il Pensiero Scientifico Editore.
| Original language | English |
|---|---|
| Pages (from-to) | 289-295 |
| Number of pages | 7 |
| Journal | Tumori |
| Volume | 100 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Chemotherapy
- Limited stage
- Prophylactic cranial irradiation
- Radiotherapy
- Small cell lung cancer
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Medicine(all)
Cite this
Radiotherapy timing in the treatment of limited-stage small cell lung cancer : The impact of thoracic and brain irradiation on survival. / Scotti, Vieri; Meattini, Icro; Franzese, Ciro; Saieva, Calogero; Bertocci, Silvia; Meacci, Fiammetta; Furfaro, Ilaria; Scartoni, Daniele; Cecchini, Sara; Desideri, Isacco; Ferrari, Katia; Bruni, Alessio; Cardillo, Carla De Luca; Bastiani, Paolo; Agresti, Benedetta; Mangoni, Monica; Livi, Lorenzo; Biti, Giampaolo.
In: Tumori, Vol. 100, No. 3, 2014, p. 289-295.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Radiotherapy timing in the treatment of limited-stage small cell lung cancer
T2 - The impact of thoracic and brain irradiation on survival
AU - Scotti, Vieri
AU - Meattini, Icro
AU - Franzese, Ciro
AU - Saieva, Calogero
AU - Bertocci, Silvia
AU - Meacci, Fiammetta
AU - Furfaro, Ilaria
AU - Scartoni, Daniele
AU - Cecchini, Sara
AU - Desideri, Isacco
AU - Ferrari, Katia
AU - Bruni, Alessio
AU - Cardillo, Carla De Luca
AU - Bastiani, Paolo
AU - Agresti, Benedetta
AU - Mangoni, Monica
AU - Livi, Lorenzo
AU - Biti, Giampaolo
PY - 2014
Y1 - 2014
N2 - Aims and background. Small cell lung cancer is an aggressive histologic subtype of lung cancer in which the role of chemotherapy and radiotherapy has been well established in limited-stage disease. We retrospectively reviewed a series of limitedstage small cell lung cancers treated with chemotherapy and thoracic and brain radiotherapy. Methods and study design. A total of 124 patients affected by limited-stage small cell lung cancer has been treated over 10 years in our Institute. Fifty-three patients (42.8%) had concomitant radio-chemotherapy treatment and 71 patients (57.2%) a sequential treatment. Eighty-eight patients (70.9%) underwent an association of a platinum-derived drug (cisplatinum or carboplatinum) and etoposide. Prophylactic cranial irradiation was planned in all patients with histologically proven complete response to primary radio-chemotherapy. Results. With a mean follow-up of 2.2 years, complete response was obtained in 50.8% of cases. We found a significant difference between different radio-chemotherapy association approaches (P = 0.007): percentages of overall survival were respectively 10.0%, 12.9% and 5.6% in early, late concomitant and sequential radiochemotherapy timing. Cranial prophylaxis did not seem to influence overall survival (P = 0.21) or disease-free survival for local relapse (P = 0.34). Conclusions. Concomitant radio-chemotherapy is the best approach according to our experience. Our results show a benefit of prophylactic cranial irradiation in distant metastasis-free survival. Copyright - Il Pensiero Scientifico Editore.
AB - Aims and background. Small cell lung cancer is an aggressive histologic subtype of lung cancer in which the role of chemotherapy and radiotherapy has been well established in limited-stage disease. We retrospectively reviewed a series of limitedstage small cell lung cancers treated with chemotherapy and thoracic and brain radiotherapy. Methods and study design. A total of 124 patients affected by limited-stage small cell lung cancer has been treated over 10 years in our Institute. Fifty-three patients (42.8%) had concomitant radio-chemotherapy treatment and 71 patients (57.2%) a sequential treatment. Eighty-eight patients (70.9%) underwent an association of a platinum-derived drug (cisplatinum or carboplatinum) and etoposide. Prophylactic cranial irradiation was planned in all patients with histologically proven complete response to primary radio-chemotherapy. Results. With a mean follow-up of 2.2 years, complete response was obtained in 50.8% of cases. We found a significant difference between different radio-chemotherapy association approaches (P = 0.007): percentages of overall survival were respectively 10.0%, 12.9% and 5.6% in early, late concomitant and sequential radiochemotherapy timing. Cranial prophylaxis did not seem to influence overall survival (P = 0.21) or disease-free survival for local relapse (P = 0.34). Conclusions. Concomitant radio-chemotherapy is the best approach according to our experience. Our results show a benefit of prophylactic cranial irradiation in distant metastasis-free survival. Copyright - Il Pensiero Scientifico Editore.
KW - Chemotherapy
KW - Limited stage
KW - Prophylactic cranial irradiation
KW - Radiotherapy
KW - Small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=84921675152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921675152&partnerID=8YFLogxK
U2 - 10.1700/1578.17206
DO - 10.1700/1578.17206
M3 - Article
C2 - 25076240
AN - SCOPUS:84921675152
VL - 100
SP - 289
EP - 295
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 3
ER -